Ixekizumab for psoriasis

Tsuda, Kenji; Tanimoto, Tetsuya; Takenouchi, Seiji; Sakaue, Saori; Komatsu, Tsunehiko

doi:10.1016/s0140-6736(16)00047-7

Cited by 1 publication

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nowadays, psoriasis sufferers are treated with a variety of agents, including corticosteroids and immunosuppressants, especially the latter. As the investigations intensified, drugs affecting specific targets have been developed, such as the human monoclonal antibodies etanercept (targeting TNF-α), ustekinumab (targeting IL-12p40), and ixekizumab and brodalumab (targeting IL-17 receptor A). − These antibody-based immunomodulators can have strong therapeutic effects in early treatment, whereas they cannot be used for a long term due to the immune deregulation they cause . The classical immunosuppressants cyclosporine A (CsA) and tacrolimus (FK506) are often used for moderate-to-severe psoriasis. , Although they can relieve the psoriasis symptoms in the short term, they also lead to serious hepatotoxicity and nephrotoxicity, , and, what is worse, once patients discontinue to take it, they may experience more serious symptoms .…”

Section: Introductionmentioning

confidence: 99%

Isogarcinol Extracted from Garcinia mangostana L. Ameliorates Imiquimod-Induced Psoriasis-like Skin Lesions in Mice

Chen

Han²,

et al. 2017

J. Agric. Food Chem.

View full text Add to dashboard Cite

Isogarcinol (YDIS), a natural compound extracted from Garcinia mangostana L., has a significant immunosuppressive effect on systemic lupus erythematosus and rheumatoid arthritis. This paper reports that it reduced imiquimod-induced psoriasis-like skin lesions in mice. It strongly attenuated the aberrant proliferation and differentiation of keratinocytes. Moreover, the expression of genes involving the interleukin-23 (IL-23)/T-helper 17 (Th17) axis was significantly inhibited in the dorsal skin of the YDIS-treated mice, as was that of the other pro-inflammatory factors TNF-α, IL-2, and even interferon (IFN)-γ. Furthermore, YDIS prevented the abnormal distribution of T cell types and suppressed the differentiation of CD4 T cells into Th17 cells in the spleens of mice exposed to imiquimod. Interestingly, it elevated numbers of regulatory T cells (Tregs) in the spleen and boosted IL-10 expression in the skin. In agreement with the above, YDIS increased serum IL-10 and reduced serum IL-17. It also caused less damage to the liver and, especially, kidneys of mice than cyclosporine A (CsA). In vitro, YDIS caused more death of HaCaT keratinocytes than CsA. It also strongly inhibited inflammatory factor expression in lipopolysaccharide (LPS)-stimulated HaCaT cells. These findings suggest that YDIS is a promising immunosuppressive agent for treating psoriasis.

show abstract